{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-007177","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.264390+00:00","generated_at":"2026-06-14T16:10:47.309279+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Dermata Therapeutics raises ~$1.8M via registered direct offering and private placement","bullets":["Sold 800,877 shares (or common stock equivalents) at $2.285 per share, gross proceeds ~$1.8M.","Issued warrants to purchase up to 800,877 shares at $2.16/share, exercisable immediately, 5.5-year term.","Placement agent H.C. Wainwright will receive 7% cash fee and warrants for 56,061 shares at $2.8563/share.","Closing expected on or about May 26, 2023, subject to customary conditions.","Proceeds to be used for general corporate purposes including R&D, clinical trials, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-007177","json":"https://secwatch.observer/filing/0001654954-23-007177.json","markdown":"https://secwatch.observer/filing/0001654954-23-007177.md","text":"https://secwatch.observer/filing/0001654954-23-007177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423007177/0001654954-23-007177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423007177/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T16:10:47.309279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3cb5dbc471258cc9642a728584b9135b413e8a57","claim":"Dermata Therapeutics, Inc. entered into Purchase Agreement with the investors named on the signature pages thereto valued at approximately $1.8 million (effective 2023-05-23).","evidence_excerpt":"On May 23, 2023, Dermata Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with the investors named on the signature pages thereto (collectively, the “ Purchasers ”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 458,555 shares (the “ Shares ”) of common stock, par value $0.0001, of the Company (“ Common Stock ”) at a purchase price of $2.285 per Share and accompanying Warrant (as defined below), and (ii) 342,322 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 342,322 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) at a purchase price of $2.2849 per Pre-Funded Warrant and accompanying Warrant, for aggregate gross proceeds to the Company of approximately $1.8 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423007177/0001654954-23-007177-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investors named on the signature pages thereto"},{"label":"Value","value":"approximately $1.8 million"},{"label":"Effective","value":"2023-05-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}